



# Assessment of safety and tolerability of obinutuzumab alone or combined with chemotherapy in a broad chronic lymphocytic leukemia (CLL) patient population, including first-line and R/R patients



 971 Patients with previously untreated or relapsed/refractory CLL in Phase 3b GREEN study

## Monotherapy

 126 Obinutuzumab (G-mono)

## Combination of obinutuzumab with chemotherapy

 193 Obinutuzumab-fludarabine-cyclophosphamide (G-FC)

114 Obinutuzumab-chlorambucil (G-Clb)

538 Obinutuzumab-bendamustine (G-benda)

		G-mono	G-FC	G-Clb	G-benda	Total
AEs of any grade, %	Any	97.6	99.0	99.1	97.2	97.8
	Neutropenia	39.7	74.1	52.6	58.4	58.4
	Pyrexia	23.0	35.8	24.6	34.4	32.0
	Thrombocytopenia	22.2	35.8	31.6	31.6	31.2
	Nausea	17.5	39.4	22.8	27.1	27.8
	Anemia	15.9	26.9	22.8	24.5	23.7
First-line, (95%CI) %	Overall response rate	63.5	89.5	82.4	81.8	
	Complete response	20.6	46.4	6.2	35.7	
R/R, %(95%CI)	Overall response rate	42.2	82.5	54.3	72.8	
	Complete response	4.7	22.5	6.5	19.9	